Retrieve available abstracts of 86 articles: HTML format
Single Articles
April 2025
YAHATA T, Toujima S, Sasaki I, Iwahashi N, et al Adeno-associated virus-clustered regularly interspaced short palindromic
repeats/cas9?mediated ovarian cancer treatment targeting PD-L1.
BMC Cancer. 2025;25:749. PubMedAbstract available
TIAN L, Gao Y, Zi L, Zhe R, et al Dual Cas12a and multiplex crRNA CRISPR strategy ultrasensitive detection novel
circRNA biomarker for the diagnosis of ovarian cancer.
BMC Cancer. 2025;25:695. PubMedAbstract available
TARAPARA B, Shah F Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and
prognostic significance in hereditary breast and ovarian cancer.
BMC Cancer. 2025;25:650. PubMedAbstract available
March 2025
KIM NI, Koo JY, Kim SS, Lee JY, et al Claudin 18.2 expression profile in primary tumors and their ovarian metastases:
implications for targeted therapy.
BMC Cancer. 2025;25:540. PubMedAbstract available
WU VS, Smith A', Russell H, Bamgboje-Ayodele A, et al Assessing the impact of a self-guided digital intervention for fear of cancer
recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised
waitlist-controlled trial.
BMC Cancer. 2025;25:527. PubMedAbstract available
OLORUNFEMI G, Libhaber E, Ezechi OC, Musenge E, et al Trends in national and ethnic burden of ovarian cancer mortality in South Africa
(1999-2018): a population based, age-period-cohort and join point regression
analyses.
BMC Cancer. 2025;25:515. PubMedAbstract available
MARBACH D, Brouer-Visser J, Brennan L, Wilson S, et al Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor)
and atezolizumab (PD-L1 inhibitor).
BMC Cancer. 2025;25:500. PubMedAbstract available
WANG H, Tu T, Yin L, Liu Z, et al Single nucleotide polymorphisms in ovarian cancer impacting lipid metabolism and
prognosis: an integrated TCGA database analysis.
BMC Cancer. 2025;25:462. PubMedAbstract available
February 2025
QIN Y, Chen XY, Cao F, Liu JC, et al Pre- and post-diagnosis dietary patterns and overall survival in patients with
epithelial ovarian cancer: a prospective cohort study.
BMC Cancer. 2025;25:363. PubMedAbstract available
SHI W, Zhang Y, Cheng S, Zhao Y, et al Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer
patients, high-risk populations, and healthy controls to identify factors and
biomarkers associated with disease diagnosis and prognosis.
BMC Cancer. 2025;25:355. PubMedAbstract available
ZHANG H, Liu M, Zhong H, Ma L, et al Mechanistic role of FN1 in LAIR-1 mediated downregulation of ovarian cancer cell
proliferation.
BMC Cancer. 2025;25:339. PubMedAbstract available
LI Y, Song W, Gao P, Guan X, et al Global, regional, and national burden of breast, cervical, uterine, and ovarian
cancer and their risk factors among women from 1990 to 2021, and projections to
2050: findings from the global burden of disease study 2021.
BMC Cancer. 2025;25:330. PubMedAbstract available
YANG N, Zhou X, Gong Y, Deng Z, et al The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.
BMC Cancer. 2025;25:294. PubMedAbstract available
YE Q, Qi Y, Liu J, Hu Y, et al A predictive model for recurrence in patients with borderline ovarian tumor based
on neural multi-task logistic regression.
BMC Cancer. 2025;25:281. PubMedAbstract available
GUPTA VG, Roby KF, Pathak HB, Godwin AK, et al The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic
murine model.
BMC Cancer. 2025;25:233. PubMedAbstract available
January 2025
KAUTZ-FREIMUTH S, Shukri A, Stracke C, Isselhard A, et al Factors influencing role preferences in decision-making of healthy women with
BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision
coaching trial.
BMC Cancer. 2025;25:164. PubMedAbstract available
CHEN W, Yan L, Li Q, Zhou S, et al Molecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese
patients using the TCGA molecular classification of endometrial cancer.
BMC Cancer. 2025;25:90. PubMedAbstract available
December 2024
WANG X, Tian W, Wang N, Yang X, et al Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian
cancer: an in vitro and in vivo study.
BMC Cancer. 2024;24:1593. PubMedAbstract available
ZHANG Y, Guan Y, Xiao X, Xu S, et al Circulating tumor DNA detection improves relapse prediction in epithelial ovarian
cancer.
BMC Cancer. 2024;24:1565. PubMedAbstract available
HUO C, Wu B, Ye D, Xu M, et al New prognostic index for neoadjuvant chemotherapy outcome in patients with
advanced high-grade serous ovarian cancer.
BMC Cancer. 2024;24:1536. PubMedAbstract available
SCHMIDT M, Vernooij R, van Nuland M, Smeijsters E, et al Impaired liver function: effect on paclitaxel toxicity, dose modifications and
overall survival.
BMC Cancer. 2024;24:1553. PubMedAbstract available
ANDRIKOPOULOU A, Zagouri F, Goula K, Haidopoulos D, et al Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing
gynecological malignancies.
BMC Cancer. 2024;24:1503. PubMedAbstract available
November 2024
IYOSHI S, Kimura M, Yoshihara M, Kunishima A, et al Detailed analysis of the histology-specific impact of ascites volume on the
outcome of epithelial ovarian cancer: a multi-institutional retrospective cohort
study.
BMC Cancer. 2024;24:1479. PubMedAbstract available
MENG Y, Meng Y, Zheng H, Huo J, et al METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via
regulation of the mTOR/AKT pathway and its link to the tumor immune
microenvironment.
BMC Cancer. 2024;24:1455. PubMedAbstract available
QIAN C, Xing Y, Cheng W Causal effect between breast cancer and ovarian cancer: a two-sample mendelian
randomization study.
BMC Cancer. 2024;24:1433. PubMedAbstract available
CHAO A, Huang CY, Yu W, Lin CY, et al Molecular profiling reveals novel therapeutic targets and clonal evolution in
ovarian clear cell carcinoma.
BMC Cancer. 2024;24:1403. PubMedAbstract available
FU YP, Lin H, Ou YC, Wu CH, et al Bevacizumab as a mitigating factor for the impact of high systemic
immune-inflammation index on chemorefractory in advanced epithelial ovarian
cancer.
BMC Cancer. 2024;24:1377. PubMedAbstract available
MAURER T, Belau MH, Zyriax BC, Welsch G, et al Study protocol of an exercise and nutrition intervention for ovarian cancer
patients during and after first-line chemotherapy (BENITA) - a randomized
controlled trial.
BMC Cancer. 2024;24:1379. PubMedAbstract available
YANG S, Wang J, Du Z, Sheng C, et al An in vitro investigation into the cytotoxic impact of antigen-presenting
dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells.
BMC Cancer. 2024;24:1364. PubMedAbstract available
October 2024
MOUSAVI A, Eshraghi N, Akhavan S, Sheikhhasani S, et al Clinical features and survival rate of patients with ovarian granulosa cell tumor
in Iran; a 10-year retrospective study.
BMC Cancer. 2024;24:1318. PubMedAbstract available
CARUCCI M, Clamp A, Zhou C, Hurt C, et al The VALTIVE1 study protocol: a study for the validation of Tie2 as the first
tumour vascular response biomarker for VEGF inhibitors.
BMC Cancer. 2024;24:1309. PubMedAbstract available
ZHAO JJ, Zhao J, Lin F, Xu LL, et al A quinoline-2-thione derivative as a novel chemotherapy drug candidate displays
anti-tumor activity in vitro and in vivo.
BMC Cancer. 2024;24:1272. PubMedAbstract available
September 2024
SHUANG T, Wu S, Zhao Y, Yang Y, et al The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous
epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian
cancer cells.
BMC Cancer. 2024;24:1213. PubMedAbstract available
August 2024
LIAO W, Li J, Feng W, Kong W, et al Pan-immune-inflammation value: a new prognostic index in epithelial ovarian
cancer.
BMC Cancer. 2024;24:1052. PubMedAbstract available
LIU D, Li R, Wang Y, Li D, et al Identification and validation of genes associated with prognosis of
cisplatin-resistant ovarian cancer.
BMC Cancer. 2024;24:508. PubMedAbstract available
July 2024
JI J, Bi F, Zhang X, Zhang Z, et al Single-cell transcriptome analysis revealed heterogeneity in glycolysis and
identified IGF2 as a therapeutic target for ovarian cancer subtypes.
BMC Cancer. 2024;24:926. PubMedAbstract available
RUBIO MJ, Manzano A, de Sande LM, Estevez-Garcia P, et al Retrospective multicenter study of elderly patients with platinum-sensitive
relapsed ovarian cancer treated with trabectedin and pegylated liposomal
doxorubicin (pld) in a real-world setting: a geico study.
BMC Cancer. 2024;24:803. PubMedAbstract available
June 2024
DE MORAES FCA, Sudo RYU, Souza MEC, Fernandes MR, et al The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis
of 50,402 patients.
BMC Cancer. 2024;24:712. PubMedAbstract available
BENTESTUEN M, Ladekarl M, Knudsen A, Zacho HD, et al Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging
patients with ovarian cancer: study protocol for a prospective clinical trial.
BMC Cancer. 2024;24:699. PubMedAbstract available
THOREL L, Divoux J, Lequesne J, Babin G, et al The OVAREX study: Establishment of ex vivo ovarian cancer models to validate
innovative therapies and to identify predictive biomarkers.
BMC Cancer. 2024;24:701. PubMedAbstract available
May 2024
LI J, Yang Z, Wang T, Li M, et al Causal relationship between lipid-lowering drugs and ovarian cancer, cervical
cancer: a drug target mendelian randomization study.
BMC Cancer. 2024;24:667. PubMedAbstract available
SOLHEIM ET, Gerking Y, Krakenes T, Herdlevaer I, et al Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell
proliferation following knockout of CDR2L.
BMC Cancer. 2024;24:645. PubMedAbstract available
WANG T, Wang X, Wu J, Li X, et al Causal relationship between thyroid dysfunction and ovarian cancer: a two-sample
Mendelian randomization study.
BMC Cancer. 2024;24:629. PubMedAbstract available
LI C, Cui Q, Wang X, Yao S, et al CA-125 elimination rate constant K (KELIM) as a promising predictor of complete
cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients:
a retrospective study from two Chinese hospitals.
BMC Cancer. 2024;24:609. PubMedAbstract available
QUAN C, Chen X, Wen H, Wu X, et al Prognostic factors and the role of primary debulking in operable stage IVB
ovarian cancer with supraclavicular lymph node metastasis: a retrospective study
in Chinese patients.
BMC Cancer. 2024;24:565. PubMedAbstract available
XIE W, Zhang L, Shen J, Lai F, et al Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by
promoting pyroptosis.
BMC Cancer. 2024;24:551. PubMedAbstract available
April 2024
CAI X, Lin J, Liu L, Zheng J, et al A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
BMC Cancer. 2024;24:515. PubMedAbstract available
DE OLIVEIRA FERREIRA C, Carneiro VCG, Araujo Mariz C Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer
treated in the Public Health System.
BMC Cancer. 2024;24:499. PubMedAbstract available
March 2024
FANG CH, Cheng WF, Cheng YF, Lan KL, et al Characterization of tumoricidal activities mediated by a novel immune cell
regimen composing interferon-producing killer dendritic cells and tumor-specific
cytotoxic T lymphocytes.
BMC Cancer. 2024;24:395. PubMedAbstract available
ALWAFAI Z, Beck MH, Fazeli S, Gurtler K, et al Accuracy of endometrial sampling in the diagnosis of endometrial cancer: a
multicenter retrospective analysis of the JAGO-NOGGO.
BMC Cancer. 2024;24:380. PubMedAbstract available
YANG S, Du J, Wang W, Zhou D, et al APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer.
BMC Cancer. 2024;24:364. PubMedAbstract available
HE D, Zhang X, Chang Z, Liu Z, et al Survival time prediction in patients with high-grade serous ovarian cancer based
on (18)F-FDG PET/CT- derived inter-tumor heterogeneity metrics.
BMC Cancer. 2024;24:337. PubMedAbstract available
NIE X, Gao L, Zheng M, Wang S, et al ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian
cancer.
BMC Cancer. 2024;24:330. PubMedAbstract available
LENG Y, Kan A, Wang X, Li X, et al Contrast-enhanced CT radiomics for preoperative prediction of stage in epithelial
ovarian cancer: a multicenter study.
BMC Cancer. 2024;24:307. PubMedAbstract available
YAACOUB S, Hajj L, Khairallah A A clinicopathological study about the epidemiology of granulosa cell tumors in
Lebanon.
BMC Cancer. 2024;24:309. PubMedAbstract available
February 2024
WU M, Gu S, Yang J, Zhao Y, et al Comprehensive machine learning-based preoperative blood features predict the
prognosis for ovarian cancer.
BMC Cancer. 2024;24:267. PubMedAbstract available
YOU Y, Yang Q Glycosylation-related genes mediated prognostic signature contribute to
prognostic prediction and treatment options in ovarian cancer: based on bulk and
single?cell RNA sequencing data.
BMC Cancer. 2024;24:207. PubMedAbstract available
JAMALZADEH S, Dai J, Lavikka K, Li Y, et al Genome-wide quantification of copy-number aberration impact on gene expression in
ovarian high-grade serous carcinoma.
BMC Cancer. 2024;24:173. PubMedAbstract available
January 2024
SONG G, Sun Z, Chu M, Zhang Z, et al FBXO28 promotes cell proliferation, migration and invasion via upregulation of
the TGF-beta1/SMAD2/3 signaling pathway in ovarian cancer.
BMC Cancer. 2024;24:122. PubMedAbstract available
YU JH, Tong CJ, Huang QD, Ye YL, et al Long-term outcomes of pelvic exenterations for gynecological malignancies: a
single-center retrospective cohort study.
BMC Cancer. 2024;24:88. PubMedAbstract available
WEIGELT J, Petrosyan M, Oliveira-Ferrer L, Schmalfeldt B, et al Ovarian cancer cells regulate their mitochondrial content and high mitochondrial
content is associated with a poor prognosis.
BMC Cancer. 2024;24:43. PubMedAbstract available
December 2023
WANG H, Chen C, Wang D, Zhu Y, et al Correlation of clinicopathological and prognostic characteristics between
endometriosis-associated and primary ovarian cancer.
BMC Cancer. 2023;23:1210. PubMedAbstract available
November 2023
LIU S, Yan Y, Cui Z, Feng H, et al Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer
susceptibility among southern Chinese woman: a three-center case-control study.
BMC Cancer. 2023;23:1149. PubMedAbstract available
YANG Y, Ye X, Zhou B, Liu Y, et al Nomogram for predicting lymph node metastasis in patients with ovarian cancer
using ultrasonography: a multicenter retrospective study.
BMC Cancer. 2023;23:1121. PubMedAbstract available
VOGEL RI, Stenzel AE, Lee H, Hunter-Schlichting D, et al Prevalence of active cytomegalovirus infection at diagnosis of ovarian cancer and
during chemotherapy and subsequent changes in cognitive functioning.
BMC Cancer. 2023;23:1057. PubMedAbstract available
October 2023
KIM YB, Byun HK, Wee CW, Kim H, et al Study protocol for prospective multi-institutional phase III trial of standard of
care therapy with or without stereotactic ablative radiation therapy for
recurrent ovarian cancer (SABR-ROC).
BMC Cancer. 2023;23:1014. PubMedAbstract available
ELSHAMI M, Al-Madhoun S, Alser M, Al-Slaibi I, et al Anticipated time to seek medical advice for possible ovarian cancer symptoms and
perceived barriers to early presentation among Palestinian women: a national
cross-sectional study.
BMC Cancer. 2023;23:975. PubMedAbstract available
DOBILAS A, Jansaker F, Li X, Sundquist K, et al Risks of non-ovarian cancers in women with borderline ovarian tumor: a national
cohort study in Sweden.
BMC Cancer. 2023;23:951. PubMedAbstract available
September 2023
CHEN L, Tang Q, Zhang K, Huang Q, et al Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer:
metabolic biomarkers and biological implications.
BMC Cancer. 2023;23:844. PubMedAbstract available
August 2023
O'BRIEN S, Butticello M, Thompson C, Wilson B, et al Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of
Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
BMC Cancer. 2023;23:775. PubMedAbstract available
OFVERHOLM A, Torngren T, Rosen A, Arver B, et al Extended genetic analysis and tumor characteristics in over 4600 women with
suspected hereditary breast and ovarian cancer.
BMC Cancer. 2023;23:738. PubMedAbstract available
July 2023
CHITRANGI S, Vaity P, Jamdar A, Bhatt S, et al Patient-derived organoids for precision oncology: a platform to facilitate
clinical decision making.
BMC Cancer. 2023;23:689. PubMedAbstract available
BATISTA MP, Roffe M, Romero I, Lopez-Guerrero JA, et al Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal
aberrations linked to survival and progression.
BMC Cancer. 2023;23:613. PubMedAbstract available
GEBHART P, Singer CF, Gschwantler-Kaulich D CA125 Levels in BRCA mutation carriers - a retrospective single center cohort
study.
BMC Cancer. 2023;23:610. PubMedAbstract available
CHEN S, Lu H, Jiang S, Li M, et al An analysis of clinical characteristics and prognosis of endometrioid ovarian
cancer based on the SEER database and two centers in China.
BMC Cancer. 2023;23:608. PubMedAbstract available
June 2023
HALLSSON LR, Sroczynski G, Engel J, Siebert U, et al Decision-analytic evaluation of the comparative effectiveness and
cost-effectiveness of strategies to prevent breast and ovarian cancer in German
women with BRCA-1/2 mutations.
BMC Cancer. 2023;23:590. PubMedAbstract available
LI X, Li X, Hu Y, Liu O, et al PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family
in ovarian cancer: based on bioinformatics analysis and in vitro validation.
BMC Cancer. 2023;23:573. PubMedAbstract available
MALEKI Z, Vali M, Nikbakht HA, Hassanipour S, et al Survival rate of ovarian cancer in Asian countries: a systematic review and
meta-analysis.
BMC Cancer. 2023;23:558. PubMedAbstract available
May 2023
DUAN C, Li K, Pan X, Wei Z, et al Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a
Chinese clinical center.
BMC Cancer. 2023;23:489. PubMedAbstract available
FANALE D, Brando C, Corsini LR, Cutaia S, et al Low plasma PD-L1 levels, early tumor onset and absence of peritoneal
carcinomatosis improve prognosis of women with advanced high-grade serous ovarian
cancer.
BMC Cancer. 2023;23:437. PubMedAbstract available
April 2023
MELKI R, Melloul M, Aissaoui S, El Harroudi T, et al Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2
c.1310_1313delAAGA mutations in breast cancer families from Northerstern region
of Morocco: evidence of geographical specificity and high relevance for genetic
counseling.
BMC Cancer. 2023;23:339. PubMedAbstract available
LI J, Liang H, Xiao W, Wei P, et al Whole-exome mutational landscape and molecular marker study in mucinous and clear
cell ovarian cancer cell lines 3AO and ES2.
BMC Cancer. 2023;23:321. PubMedAbstract available
REIJONEN M, Holopainen E, Arponen O, Kononen M, et al Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion
coefficient values in patients with ovarian cancer.
BMC Cancer. 2023;23:299. PubMedAbstract available
March 2023
LIU S, Feng S, Du F, Zhang K, et al Association of smoking, alcohol, and coffee consumption with the risk of ovarian
cancer and prognosis: a mendelian randomization study.
BMC Cancer. 2023;23:256. PubMedAbstract available
BATES KM, Vathiotis I, MacNeil T, Ahmed FS, et al Spatial characterization and quantification of CD40 expression across cancer
types.
BMC Cancer. 2023;23:220. PubMedAbstract available
June 2021
REID BM, Vyas S, Chen Z, Chen A, et al Morphologic and molecular correlates of EZH2 as a predictor of platinum
resistance in high-grade ovarian serous carcinoma.
BMC Cancer. 2021;21:714. PubMedAbstract available